• 1.

    Hasnain MG, Shomik MS, Ghosh P, Rashid MO, Hossain MS, Hamano S, Mondal D, 2016. Case report: post-kala-azar dermal leishmaniasis without previous history of visceral leishmaniasis. Am J Trop Hyg 95: 13831385.

    • Search Google Scholar
    • Export Citation
  • 2.

    WHO, 2012. Post Kala-azar Dermal Leishmaniasis: A Manual for Case Management and Control [Internet]. A report of a WHO consultative meeting, Kolkata, India, July 2–3 2012. Available at: http://apps.who.int/iris/bitstream/10665/78608/1/9789241505215_eng.pdf Accessed July 16, 2016.

  • 3.

    Mondal D, Hamano S, Hasnain MG, Stocker AR, 2014. Challenges for management of post kala-azar dermal leishmaniasis and future directions. Res Rep Trop Med 5: 105111.

    • Search Google Scholar
    • Export Citation
  • 4.

    Molina R, Ghosh D, Carrillo E, Monnerat S, Bern C, Mondal D, Alvar J, 2017. Infectivity of post-kala-azar dermal leishmaniasis patients to sand flies: revisiting a proof of concept in the context of the kala-azar elimination program in the Indian subcontinent. Clin Infect Dis 65: 150153.

    • Search Google Scholar
    • Export Citation
  • 5.

    Mondal D, Nasrin KN, Huda MM, Kabir M, Hossain MS, Kroeger A, Thomas T, Haque R, 2010. Enhanced case detection and improved diagnosis of PKDL in a kala-azar endemic areas in Bangladesh. PLoS Negl Trop Dis 4: e832.

    • Search Google Scholar
    • Export Citation
  • 6.

    National guideline for kala-azar case management, 2015. Kala-azar Elimination Program. Communicable Disease Control. Disease control unit. Directorate general health services. Ministry of health and family welfare. Bangladesh: Government of Bangladesh.

  • 7.

    Ramesh V, Ansari NA, Jain RK, Salotra P, 2007. Oral miltefosine in the treatment of post-kala-azar dermal Leishmaniasis. Clin Exp Dermatol 33: 103104.

    • Search Google Scholar
    • Export Citation
  • 8.

    Ramesh V, Singh R, Avishek K, Verma A, Deep DK, Verma S, Salotra P, 2015. Decline in clinical efficacy of oral miltefosine in treatment of post kala-azar dermal leishmaniasis (PKDL) in India. PLoS Negl Trop Dis 9: e0004093.

    • Search Google Scholar
    • Export Citation
  • 9.

    Hasnain MG, Basher A, Nath P, Ghosh P, Hossain F, Hossain MS, Mondal D, 2016. Polymerase chain reaction in the diagnosis of visceral leishmaniasis recurrence in the setting of negative splenic smears. Am J Trop Hyg 94: 99101.

    • Search Google Scholar
    • Export Citation
  • 10.

    Subhashree AR, Parameaswari PJ, Shanthi B, Revathy C, Parijatham BO, 2012. The reference intervals for the haematological parameters in healthy adult population of Chennai, southern India. J Clin Diagn Res 6: 16751680.

    • Search Google Scholar
    • Export Citation
  • 11.

    Diana Nicoll C, 2007. Appendix: therapeutic drug monitoring and laboratory reference ranges. Stephen JM, Maxine AP, eds. Current Medical Diagnosis and Treatment, 46th edition. Columbus, OH: McGraw Hill, 1767–1775.

  • 12.

    Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ, 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46: 828833.

    • Search Google Scholar
    • Export Citation
 
 
 

 

 
 
 

 

 

 

 

 

 

Case Report: Treatment of Widespread Nodular Post kala-Azar Dermal Leishmaniasis with Extended-Dose Liposomal Amphotericin B in Bangladesh: A Series of Four Cases

View More View Less
  • 1 Infectious and Tropical Medicine Department, Mymensingh Medical College and Hospital (MMCH), Mymensingh, Bangladesh;
  • | 2 Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh;
  • | 3 Centre for Clinical Epidemiology and Biostatistics (CCEB), School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle (UoN), New South Wales (NSW), Australia;
  • | 4 National Kala-azar Elimination Program (NKEP), Directorate General Health Services (DGHS); Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB), Dhaka, Bangladesh;
  • | 5 Disease Control Unit, Directorate General Health Services (DGHS), Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB), Dhaka, Bangladesh;
  • | 6 Department of Medicine, Shaheed Suhrawardi Medical College and Hospital (SSMCH), Dhaka, Bangladesh;
  • | 7 Dev Care Foundation, Dhaka, Bangladesh

Post kala-azar dermal leishmaniasis (PKDL) is a skin manifestation which usually appears after visceral leishmaniasis. It is now proved that PKDL patients serve as a reservoir for anthropometric leishmanial transmission. Hence, to achieve the kala-azar elimination target set by the World Health Organization in the Indian Subcontinent, PKDL cases should be given priority. The goal of treatment for PKDL should be early reepithelizlization and rapid cure, but unfortunately this has been difficult to achieve, especially for patients with severe lesions. Therefore, we describe here four cases of PKDL who had widespread nodular and macular lesions and were treated with two cycles of LAmB doses with 20 mg/kg body weight divided into four equal doses (each dose contains 5 mg/kg) administered every alternate day. This treatment schedule achieved 100% treatment success with the minimal safety concern.

Author Notes

Address correspondence to Ariful Basher, Infection and Tropical Medicine, Mymensingh Medical College Hospital (MMCH), Mymensingh, Bangladesh. E-mail: ariful.dr@gmail.com

Financial Support: There was no financial support for conducting the activity.

Authors’ addresses: Ariful Basher, Proggananda Nath, Muhammod Abdul Mukit, and Azim Anwarul, Infectious and Tropical Medicine Department, Mymensingh Medical College Hospital (MMCH), Mymensingh, Bangladesh, E-mails: ariful.dr@gmail.com, progganath@yahoo.com, mukit.pharma@gmail.com, and azimanwarul@gmail.com. Shomik Maruf, Fatima Aktar, Rupen Nath, and Dinesh Mondal, Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh, E-mails: shomik_stj@yahoo.com, fatimaaktar61@gmail.com, rupennath77@gmail.com, and din63d@icddrb.org. Md Golam Hasnain and Abul Hasnat Milton, Centre for Clinical Epidemiology and Biostatistics (CCEB), School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle (UoN), Newcastle, Australia, E-mails: mdgolam.hasnain@uon.edu.au and milton.hasnat@newcastle.edu.au. AFM Akhtar Hossain, National Kala-azar Elimination Program (NKEP), Directorate General Health Services (DGHS), Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB), Dhaka, Bangladesh, E-mail: afmhossain@yahoo.com. Abul Khair Mohammad Shamsuzzaman, Disease Control Unit, Directorate General Health Services (DGHS), Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB), Dhaka, Bangladesh, E-mail: ariful.dr@gmail.com. Ridwanur Rahman, Department of Medicine, Shaheed Suhrawardi Medical College and Hospital (SSMCH), Dhaka, Bangladesh, E-mail: ridwanurr@yahoo.com. M. A. Faiz, Dev Care Foundation, Dhaka, Bangladesh, E-mail: drmafaiz@gmail.com.

Save